PTK2 and neoplasm: EC-inherent FAK, in turn, protects tumor cells from DNA-damaging doxorubicin chemotherapy through FAK-triggered activation of the nuclear factor “kappa-light-chain-enhancer” of activated B-cells (NF-kB) TF and consecutive EC cytokine expression.